Chandra Bhagat Pharma Ltd
₹ 44.0
1.13%
08 Jun
- close price
About
Incorporated in 2003, Chandra Bhagat Pharma Ltd manufactures chemical and pharmaceutical products.[1]
Key Points
- Market Cap ₹ 33.2 Cr.
- Current Price ₹ 44.0
- High / Low ₹ 59.0 / 29.7
- Stock P/E 10.9
- Book Value ₹ 43.9
- Dividend Yield 0.00 %
- ROCE 12.1 %
- ROE 9.67 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Stock is trading at 1.00 times its book value
- Promoter holding has increased by 0.83% over last quarter.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 10.5% over past five years.
- Company has a low return on equity of 5.92% over last 3 years.
- Earnings include an other income of Rs.3.35 Cr.
- Company has high debtors of 171 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 61 | 80 | 90 | 97 | 106 | 94 | 71 | 94 | 120 | 221 | 87 | 116 | |
| 58 | 76 | 85 | 92 | 102 | 91 | 67 | 91 | 116 | 228 | 88 | 112 | |
| Operating Profit | 3 | 3 | 4 | 5 | 5 | 3 | 4 | 3 | 3 | -7 | -1 | 4 |
| OPM % | 5% | 4% | 5% | 5% | 4% | 3% | 5% | 3% | 3% | -3% | -2% | 3% |
| 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 11 | 5 | 3 | |
| Interest | 2 | 3 | 4 | 4 | 4 | 3 | 4 | 3 | 2 | 1 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Profit before tax | 1 | 1 | 1 | 2 | 1 | 0 | 0 | 1 | 1 | 2 | 1 | 4 |
| Tax % | 39% | 51% | 27% | 33% | 22% | 26% | 32% | 27% | 22% | 33% | 26% | 26% |
| 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 2 | 1 | 3 | |
| EPS in Rs | 10.29 | 8.37 | 15.79 | 24.64 | 10.29 | 0.41 | 0.25 | 1.06 | 1.21 | 2.03 | 1.14 | 4.04 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 10% |
| 3 Years: | -1% |
| TTM: | 34% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | 74% |
| 3 Years: | 50% |
| TTM: | 330% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -5% |
| 3 Years: | -33% |
| 1 Year: | -24% |
| Return on Equity | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 5% |
| 3 Years: | 6% |
| Last Year: | 10% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.42 | 0.42 | 0.42 | 0.42 | 0.67 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| Reserves | 6 | 6 | 7 | 8 | 14 | 18 | 18 | 19 | 20 | 21 | 22 | 26 |
| 28 | 28 | 22 | 22 | 31 | 30 | 27 | 21 | 19 | 16 | 21 | 17 | |
| 8 | 10 | 26 | 28 | 37 | 19 | 19 | 25 | 14 | 56 | 51 | 45 | |
| Total Liabilities | 42 | 44 | 56 | 58 | 83 | 75 | 72 | 72 | 61 | 102 | 102 | 94 |
| 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 3 | 3 | 3 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 5 | 1 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| 41 | 44 | 51 | 56 | 78 | 74 | 71 | 72 | 60 | 99 | 99 | 90 | |
| Total Assets | 42 | 44 | 56 | 58 | 83 | 75 | 72 | 72 | 61 | 102 | 102 | 94 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | -9 | -6 | 4 | -7 | 8 | 12 | 5 | 6 | -6 | 9 | |
| 0 | 0 | 0 | -0 | -0 | 0 | 0 | 0 | -0 | -2 | -1 | -0 | |
| 0 | 0 | 8 | 7 | -4 | 7 | -6 | -10 | -4 | -6 | 2 | -6 | |
| Net Cash Flow | 0 | 0 | -1 | -0 | -0 | -0 | 2 | 3 | 1 | -1 | -5 | 2 |
| Free Cash Flow | 0 | 0 | -9 | -6 | 4 | -7 | 8 | 12 | 5 | 4 | -7 | 8 |
| CFO/OP | 0% | 0% | -200% | -129% | 98% | -238% | 229% | 440% | 164% | -94% | 354% | 250% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 71 | 66 | 80 | 67 | 90 | 54 | 80 | 58 | 25 | 65 | 151 | 171 |
| Inventory Days | 177 | 123 | 133 | 145 | 174 | 187 | 215 | 153 | 100 | 15 | 3 | 18 |
| Days Payable | 43 | 33 | 81 | 69 | 117 | 53 | 79 | 12 | 11 | 23 | 45 | 124 |
| Cash Conversion Cycle | 205 | 156 | 132 | 143 | 146 | 188 | 216 | 199 | 114 | 57 | 110 | 65 |
| Working Capital Days | 166 | 134 | 125 | 138 | 83 | 148 | 177 | 104 | 75 | 36 | 115 | 82 |
| ROCE % | 10% | 10% | 15% | 17% | 13% | 7% | 7% | 9% | 7% | 8% | 6% | 12% |
Insights
In beta| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Number of Permanent Employees Number |
|
||||||
| Domestic Sales Revenue INR Lacs |
|||||||
| Export Sales Revenue INR Lacs |
|||||||
| Trade Receivables Turnover Ratio Times |
|||||||
| Customer Concentration (Top 5 Customers Share of Revenue) Percentage |
|||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Financial Result For Period Ended 31St March, 2026
25 May - Board approved audited FY26 results on 25 May 2026; auditors issued unmodified opinion.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 25Th May 2026 For Approval Of Audited Result As On 31St March, 2026.
25 May - Board approved FY26 audited results for year ended 31 March 2026; auditors issued unmodified opinion.
-
Board Meeting Intimation for Approval Of Audited Financial Results As On 31St March, 2026
18 May - Board meeting on 25 May 2026 to consider audited half-year and year-end financial statements.
-
Certificate For NON-Applicability Of Corporate Governance As On 31 March 2026.
21 Apr - Company states corporate governance provisions and Q4 FY2026 report are not applicable under Regulation 15.
-
Disclosure Under Regulation 30.
1 Apr - Opened Dubai international representative office; Certificate of Formation dated 31-Mar-2026.
Business Overview:[1][2]
a) CBPL, under the brand name CBC, is engaged in manufacturing pharmaceutical formulations such as intravenous (IV) and intramuscular (IM) injections, tablets, and capsules
for both domestic and international markets.
b) The company operates primarily through contract manufacturing and job work arrangements, while maintaining
a diversified product portfolio across a multiple therapeutic segments including oncology, antibiotics, anesthesia, hormones, orthopedics, cardiology, nephrology, neurology, pediatrics, antifungal, and antiviral treatments.
c) In addition to formulations, CBPL is actively involved in the ethical promotion and marketing of Active Pharmaceutical Ingredients (APIs), specialty chemicals, and intermediates, leveraging its own distribution network and sales force.
d) Its major focus lies in supplying critical disease treatments—particularly injections, tablets, and capsules—to hospitals, healthcare centers, government institutions, NGOs, and distributors, combining sourcing, marketing, supply of both generic and branded medicines with a presence in domestic and international markets.